1. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis;Sormani;Ann Neurol,2021
2. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis;Louapre;JAMA Neurol,2020
3. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther Adv Neurol Disord,2021
4. Medistica. pvalue.io, a graphic user interface to the R statistical analysis software for scientific medical publications. Available on: https://www.pvalue.io 2020.
5. La stratégie vaccinale et la liste des publics prioritaires. Ministère des Solidarités et de la Santé;Haute Autorité de Santé,2021